DFE Pharma — full event log

In 2025, DFE Pharma will phase out fossil oil use at Cuddalore site, reducing Scope 1 emissions.

sustainability_report p.13

In 2024 DFE Pharma recalculated Scope 3 emissions for 2021-2024 using more specific data sources. 94% now based on supplier-specific amount-based data (80% from farm-level lactose supplier data), 4% industry averages, 2% financial proxies. GHG emissions ~3% lower than previously reported.

sustainability_report p.14

Data for Scope 1, 2 and 3 emissions for 2021-2023 were recalculated in 2024 after discontinuation of Quantis tool in 2023. Methodology changed from database/spend-based to more granular supplier-specific data.

sustainability_report p.44

DFE Pharma awarded EcoVadis Gold Medal in May 2024, positioning the company in the top 5% of all rated companies worldwide. Previously held Silver Medal in 2023.

sustainability_report p.33

In 2024 all EU sites operated on 100% green electricity. Renewable energy usage nearly doubled (67k→143k GJ) primarily due to biomass boiler commissioning at new MCC plant in Cuddalore, India.

sustainability_report p.13

DFE Pharma aims to achieve zero deforestation across all primary deforestation-linked commodities by December 31, 2025.

sustainability_report p.34

Goal to ensure all packaging materials used in operations are 100% recyclable by 2030, with 25% reduction in plastic use by 2030.

sustainability_report p.15

DFE Pharma launched a Biodiversity Rating process evaluating suppliers on deforestation prevention, biodiversity conservation, and animal health/welfare. 49% of revenue-based supplier volume evaluated; FLAG suppliers prioritized.

sustainability_report p.18

Global analysis on living wage completed in 2024; committed to pay above 'Fair Wage' defined living wage at all 13 global locations.

sustainability_report p.24

In 2024, DFE Pharma's reporting was consolidated into Royal Friesland Campina's framework for CSRD compliance, while broader sustainability reporting continues independently.

sustainability_report p.4

DFE Pharma is aiming to prioritize emissions reduction through direct abatement, rather than using carbon credits. The firm plans to avoid the use of offsets to achieve 2030 reduction targets. Has invested in carbon-credit-sourced renewable energy projects in the interim until sufficient renewable sources are available. No removals (DAC, BECCS, etc.) disclosed.

sustainability_report p.58

In 2025 DFE Pharma will phase out the use of fossil oil at its Cuddalore site, marking a significant step in reducing Scope 1 emissions. Biomass boiler at the new MCC plant replaces the old fossil fuel boiler. All EU sites already on 100% green electricity for Scope 2.

sustainability_report p.13

In 2024 the car lease policy was updated so every newly ordered vehicle in Germany and the Netherlands is electric. Whole fleet expected to be fully electrified within 4 years.

sustainability_report p.13

FLAG emissions constitute 75% of Scope 3 and 74% of total carbon footprint, driven by dairy/lactose raw materials. 80% of Scope 3 calculation comes directly from farm-level data provided by lactose suppliers. SBTi 30.3% Scope 3 FLAG reduction target by 2030 vs 2021. Strategy relies on supplier collaboration to drive sustainable practices and zero-deforestation commitment by end-2025.

sustainability_report p.14

SBTi-validated 42% reduction in Scope 3 emissions from purchased goods and services, upstream transportation and distribution, and end-of-life treatment of sold products by 2030 vs 2021 baseline. Non-FLAG Scope 3 represents ~25% of footprint with >90% of 'other' category being end-of-life and transport.

sustainability_report p.14

DFE Pharma awarded EcoVadis Gold Medal in May 2024, placing it in the top 5% of rated companies worldwide. Upgrade from Silver Medal in 2023.

sustainability_report p.33

DFE Pharma's near-term and FLAG targets were officially approved by SBTi: 42% absolute reduction in Scope 1&2 by 2030 vs 2021 baseline; 42% reduction in Scope 3 from purchased goods, upstream transport, and end-of-life sold products by 2030; and 30.3% reduction in Scope 3 FLAG by 2030. Targets aligned with 1.5°C pathway.

sustainability_report p.34

Commitment to ensure all packaging materials used in own operations are 100% recyclable by 2030 and to reduce plastic use by 25% by 2030.

sustainability_report p.15

DFE Pharma is aiming to prioritize emissions reduction through direct abatement rather than using carbon credits. Plans to avoid use of offsets to achieve 2030 emissions reduction targets, though it has invested in carbon credit sourced renewable energy projects in the meantime.

sustainability_report p.58

FLAG emissions dominate the carbon footprint: 75% of Scope 3 is FLAG and Scope 3 is 98% of total emissions. 80% of Scope 3 now comes directly from farm-level data provided by lactose suppliers — a rare level of granularity. DFE Pharma launched a Biodiversity Rating process for suppliers (49% of revenue-based volume already evaluated, focused on FLAG suppliers) covering deforestation, biodiversity, and animal welfare. SBTi 30.3% Scope 3 FLAG reduction target by 2030 vs 2021.

sustainability_report p.14

Three-pillar packaging circularity strategy: (1) Recycle — 100% recyclable packaging by 2030; (2) Reduce — 25% reduction in plastic use by 2030; (3) Reuse — promote re-use of packaging across operations and with partners. Packaging material separability improved from 77% (2021) to 92% (2024). Comprehensive packaging database developed to assess current status and close gaps with contract manufacturers.

sustainability_report p.15

Scope 1, 2 and 3 emissions for 2021-2023 were recalculated in 2024 with improved supplier-specific data quality. 94% of emissions now based on supplier-specific amount-based data (80% from farm-level lactose suppliers). GHG emissions ~3% lower than previously reported.

sustainability_report p.44

DFE Pharma aims to achieve zero deforestation across all primary deforestation-linked commodities by December 31, 2025.

sustainability_report p.34

Updated car lease policy in 2024: every newly ordered vehicle in Germany and Netherlands will be electric. Whole fleet expected fully electrified within 4 years.

sustainability_report p.13

All EU sites are running with 100% green electricity. The new MCC plant in Cuddalore, India is fueled by a biomass boiler, nearly doubling renewable energy consumption from 73,498 GJ (2023) to 143,037 GJ (2024). Renewables now exceed 51% of total energy. Old fossil-fuel boiler at Cuddalore to be phased out in Q1 2025. Renewable energy projects have been partly carbon-credit sourced in the interim, until sufficient direct renewable supply is available.

sustainability_report p.12

Two key drivers: optimizing manufacturing processes for efficiency and transitioning away from fossil-based energy sources. All production sites are ISO 14001 certified. Phase-out of fossil oil at Cuddalore planned for Q1 2025. Energy management software being adopted where applicable. Roadmaps in place to monitor progress toward 42% near-term Scope 1&2 reduction target by 2030 vs 2021 baseline.

sustainability_report p.13

In 2024, DFE Pharma began using EcoVadis IQ Plus to assess 100% of suppliers (by external spend) for sustainability and CSR risk. 11 on-site supplier ESG audits conducted in 2024 (vs 1 in 2023). Responsible Sourcing Policy mandatory from 2025. Engagement focused on energy, GHG emissions and waste reduction in supplier operations.

sustainability_report p.17

Commissioning of new MCC (Microcrystalline Cellulose) capacity expansion in Cuddalore, India increased overall energy use (+34% YoY) but renewable energy nearly doubled due to biomass boiler. Old fossil-oil plant runs in parallel until Q1 2025 phase-out.

sustainability_report p.12

Updated 2024 car lease policy: every newly ordered vehicle in Germany and the Netherlands will be electric. Whole company fleet expected to be fully electrified within 4 years.

sustainability_report p.13

DFE Pharma is aiming to prioritize emissions reduction through direct abatement, rather than using carbon credits. The firm plans to avoid the use of offsets to achieve its 2030 emissions reduction targets. SBTi-approved targets include land-related emissions and removals from bioenergy feedstocks (FLAG). No durable removals (DAC/BECCS/biochar) disclosed.

sustainability_report p.58

All EU sites run on 100% green electricity as of 2024. Renewable energy nearly doubled in 2024 (70k→143k GJ, ~51% of total energy) driven by a biomass boiler at the new Cuddalore MCC capacity expansion in India. The old fossil-fuel boiler runs in parallel during transition and will be phased out by end of Q1-2025. Car lease policy was updated so every newly ordered vehicle in Germany and Netherlands is electric; full fleet electrification expected within 4 years.

sustainability_report p.13

In 2024 SBTi officially approved DFE Pharma's near-term targets: 42% absolute reduction in Scope 1&2 by 2030 vs 2021 base year; 42% Scope 3 reduction (purchased goods, upstream transport, end-of-life); 30.3% Scope 3 FLAG reduction. Recognized as aligned with 1.5°C pathway.

sustainability_report p.34

Three-pronged circular packaging strategy: Recycle (100% recyclable packaging by 2030), Reduce (25% plastic reduction by 2030), Reuse (promote re-use across operations). Degree of packaging material separability improved from 77% (2021) to 92% (2024). Comprehensive database built to assess current status; active engagement with contract manufacturers to close data gaps.

sustainability_report p.15